...
首页> 外文期刊>Acta Haematologica >Comparative Study of the Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation from Human Leukocyte Antigen-Haploidentical Related and Unrelated Donors in the Treatment of Leukemia
【24h】

Comparative Study of the Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation from Human Leukocyte Antigen-Haploidentical Related and Unrelated Donors in the Treatment of Leukemia

机译:人白细胞抗原同种和无关供者同种异体造血干细胞移植治疗白血病的疗效比较研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Aims: To compare the efficacy of hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)-haploidentical related donors (RD) and unrelated donors (URD) in the treatment of leukemia. Methods: Ninety-three leukemia patients underwent allogeneic HSCT were divided into two groups: 51 cases of RD-HSCT and 42 cases of URD-HSCT. In the RD-HSCT group, a preconditioning regimen with fludarabine (Flu) + busulfan (Bu) + cytosine arabi-noside (Ara-C) was used in 42 patients and total body irradiation (TBI) + Flu + Ara-C was used in the remaining 9. Results: In the URD-HSCT group, a modified preconditioning regimen with Bu + cyclophosphamide was used in 35 patients, while the other 7 patients underwent treatment with TBI + Flu. After transplantation, the occurrence rate of grade II-IV acute graft-versus-host disease (GVHD) was 46.0 and 51.2% in the two groups. Likewise, the rate of chronic GVHD was 46.0 and 63.4%, respectively. No significant differences in the occurrence of acute and chronic GVHD were detected between the two groups. The differences in early-stage infection rate after transplantation, recurrence rate, 3-year survival rate, and disease-free survival rate between the two groups were not significant. Conclusion: HLA-haploidentical RD-HSCT with enhanced preconditioning and administration of immunosuppressants showed a clinical efficacy similar to that of URD-HSCT against leukemia, without the risk of increased infection and GVHD.
机译:目的:比较人白细胞抗原(HLA)-单亲相关供体(RD)和非相关供体(URD)的造血干细胞移植(HSCT)治疗白血病的疗效。方法:将93例接受异基因HSCT的白血病患者分为两组:RD-HSCT 51例和URD-HSCT 42例。在RD-HSCT组中,对42例患者采用氟达拉滨(Flu)+白消安(Bu)+胞嘧啶阿拉伯糖苷(Ara-C)进行预处理的方案,并采用全身照射(TBI)+ Flu + Ara-C在其余9个患者中。结果:在URD-HSCT组中,对35例患者采用了改良的Bu +环磷酰胺预处理方案,而其他7例患者则接受了TBI + Flu治疗。移植后,两组II-IV级急性移植物抗宿主病(GVHD)的发生率分别为46.0%和51.2%。同样,慢性GVHD的发生率分别为46.0%和63.4%。两组之间在急性和慢性GVHD的发生上没有显着差异。两组移植后早期感染率,复发率,3年生存率和无病生存率差异不显着。结论:具有增强的预处理和免疫抑制剂作用的HLA单倍体RD-HSCT具有与URD-HSCT相似的抗白血病临床疗效,且没有增加感染和GVHD的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号